DDInter1852 DDInter1376
Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease.[L41855,L41860] The first agent approved for the treatment of PAH was [epoprostenol], a synthetic prostacyclin that significantly increases patients' quality of life. However, the use of epoprostenol is limited due to its short half-life (3-5 min) and instability at room temperature.[A248770,A248775] The use of more stable alternatives such as treprostinil provides patients with PAH with more treatment options. Treprostinil was approved by the FDA in 2002 for the treatment of pulmonary arterial hypertension. It is available in the following routes of administration: subcut
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Treprostinil {u} (Compound) resembles {v} (Compound) Latanoprost
Treprostinil {u} (Compound) binds {v} (Gene) P2RY12
Treprostinil {u} (Compound) upregulates {v} (Gene) IL4R
Treprostinil {u} (Compound) is included by {v} (Pharmacologic Class) Vasodilation
Treprostinil {u} (Compound) downregulates {v} (Gene) CNDP2
Treprostinil {u} (Compound) causes {v} (Side Effect) Palpitations
Treprostinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capsicum
Treprostinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Reteplase
Treprostinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diflunisal
Treprostinil {u} may lead to a major life threatening interaction when taken with {v} Ramucirumab
Treprostinil (Compound) resembles Latanoprost (Compound)
Treprostinil (Compound) binds P2RY12 (Gene)
Treprostinil (Compound) upregulates IL4R (Gene)
Treprostinil (Compound) is included by Vasodilation (Pharmacologic Class)
Treprostinil (Compound) downregulates CNDP2 (Gene)
Treprostinil (Compound) causes Palpitations (Side Effect)
Treprostinil may cause a minor interaction that can limit clinical effects when taken with Capsicum
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Reteplase
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal
Treprostinil may lead to a major life threatening interaction when taken with Ramucirumab